Daiichi Sankyo and AstraZeneca’s (AZN) supplemental biologics license application for Enhertu has been accepted and granted priority review in the U.S. for the treatment of adult patients with HER2 positive breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Controversial Prasad leaving FDA, NYT reports
- AstraZeneca Halts Early KRASG12D Cancer Trial, Shifting Focus in Competitive Oncology Race
- AstraZeneca CEO Receives 101,495 Shares as Long-Term Incentive Award Vests
- AstraZeneca Executives Receive Vested Deferred Share Awards
- AstraZeneca Grants Long-Term Share Awards to CEO and CFO